Gilead Sciences, Inc. $GILD Position Lifted by MGO One Seven LLC

MGO One Seven LLC grew its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 31.0% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 17,858 shares of the biopharmaceutical company’s stock after acquiring an additional 4,231 shares during the period. MGO One Seven LLC’s holdings in Gilead Sciences were worth $2,662,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently modified their holdings of GILD. BlackRock Inc. purchased a new position in Gilead Sciences during the second quarter valued at $15,393,785,000. Legal & General Group Plc purchased a new stake in Gilead Sciences in the second quarter worth about $1,316,606,000. Deutsche Bank AG purchased a new stake in Gilead Sciences in the second quarter worth about $918,387,000. Jupiter Topco LLC purchased a new stake in Gilead Sciences in the second quarter worth about $448,021,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in shares of Gilead Sciences in the second quarter worth about $398,905,000. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Gilead Sciences Trading Down 1.7%

Shares of GILD stock opened at $167.47 on Wednesday. The company has a debt-to-equity ratio of 1.84, a quick ratio of 0.95 and a current ratio of 1.38. The stock has a fifty day simple moving average of $151.77 and a two-hundred day simple moving average of $140.25. The firm has a market capitalization of $207.72 billion, a PE ratio of -53.00 and a beta of 0.35. Gilead Sciences, Inc. has a 52-week low of $116.88 and a 52-week high of $175.65.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported $2.55 EPS for the quarter, beating the consensus estimate of $2.19 by $0.36. Gilead Sciences had a negative return on equity of 1.85% and a negative net margin of 12.47%. The business had revenue of $8.30 billion for the quarter, compared to the consensus estimate of $7.81 billion. During the same period in the previous year, the business earned $2.47 earnings per share. The business’s revenue was up 6.8% on a year-over-year basis. On average, analysts predict that Gilead Sciences, Inc. will post -1.03 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, December 30th. Investors of record on Tuesday, December 15th will be paid a dividend of $0.82 per share. This represents a $3.28 annualized dividend and a yield of 2.0%. The ex-dividend date of this dividend is Tuesday, December 15th. Gilead Sciences’s dividend payout ratio (DPR) is -103.80%.

More Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Analysts remain broadly upbeat, with several recent price-target increases, including targets as high as $200. Coverage cites Gilead’s recent execution, HIV franchise and pipeline; a separate estimate of fair value also moved higher. Gilead price target raised to $200 Gilead fair-value estimate
• Positive Sentiment: Gilead plans to present results from more than 50 studies, including late-breaking clinical data and real-world evidence, at HIV Glasgow 2026 on November 8–11. The updates could offer pipeline and franchise catalysts. Gilead HIV Glasgow presentation
• Positive Sentiment: BioNTech said it advanced a planned Phase 3 trial, pending regulatory approval, combining its candidate pumitamig with Gilead’s cancer drug Trodelvy in triple-negative breast cancer. This represents potential progress for Gilead’s oncology collaboration, though the study remains subject to approval. BioNTech quarterly results and update
• Negative Sentiment: Investors bought 16,499 GILD put options, about 107% above typical volume. The jump may signal increased hedging or bearish positioning, although options activity alone does not establish a market view.
• Negative Sentiment: CEO Daniel O’Day sold a combined 30,881 shares in two recent transactions. Both sales were made under a prearranged Rule 10b5-1 plan, which may temper their significance, but insider selling can still be viewed cautiously by investors. CEO share sale details

Insider Activity at Gilead Sciences

In other Gilead Sciences news, Director Jeffrey Bluestone sold 5,000 shares of the stock in a transaction that occurred on Thursday, August 20th. The shares were sold at an average price of $145.02, for a total transaction of $725,100.00. Following the completion of the sale, the director directly owned 10,066 shares of the company’s stock, valued at $1,459,771.32. This trade represents a 33.19% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the stock in a transaction that occurred on Thursday, October 15th. The shares were sold at an average price of $156.22, for a total transaction of $468,660.00. Following the sale, the chief financial officer directly owned 161,096 shares of the company’s stock, valued at approximately $25,166,417.12. This trade represents a 1.83% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 126,881 shares of company stock worth $19,252,455 in the last three months. Corporate insiders own 0.30% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on GILD shares. HSBC lifted their price objective on Gilead Sciences from $155.00 to $175.00 and gave the company a “buy” rating in a research report on Thursday, September 10th. Morgan Stanley boosted their price objective on Gilead Sciences from $163.00 to $183.00 and gave the company an “overweight” rating in a research note on Friday, October 30th. BMO Capital Markets reissued an “outperform” rating and issued a $184.00 target price on shares of Gilead Sciences in a report on Friday. Citigroup raised their target price on shares of Gilead Sciences from $165.00 to $188.00 and gave the stock a “buy” rating in a research note on Friday, October 30th. Finally, Sanford C. Bernstein reaffirmed an “outperform” rating and set a $175.00 price target on shares of Gilead Sciences in a report on Monday. Twenty-three equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $169.74.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company is best known for its HIV treatments, including Biktarvy, Descovy, Genvoya and Truvada, as well as therapies for chronic hepatitis B and hepatitis C. Its portfolio also includes Veklury (remdesivir), an antiviral treatment for COVID-19.

Gilead has expanded into oncology and cell therapy through products such as Trodelvy and the CAR T-cell therapies Yescarta and Tecartus, which are developed and marketed through its Kite subsidiary.